Global Hemophilia Treatment Market Outlook, Trend and Opportunity Analysis, Competitive Insights, Actionable Segmentation & Forecast 2024

Industry : Healthcare Date : May 28th, 2018
Tutorials Get 15% Discount on First Report

The global hemophilia treatment market was estimated at USD 11.65 billion in 2017 and is expected to reach USD 15.85 billion in 2024 at a CAGR of 4.02% during the forecast period. Growing numbers of patients affected with hemophilia disease, and rising awareness about its diagnosis and treatment. However, high cost of therapy may inhibit the market growth. The years used for the assessment are as follows:

Historical year: 2014, 2015 and 2016

Base year: 2017

Forecast period: 2018 – 2024

RESEARCH METHODOLOGY

The research and analysis is based on the data and information obtained from various primary and secondary sources. The data obtained is validated by interacting with the companies of the concerned domain. The steps involved in the research methodology are;

  • Obtaining historical data of the market based on news, articles, publications, annual reports, white papers, surveys, and other secondary sources
  • Interacting with key opinion leaders of the market and developing data points based on interaction with them
  • Study of past trends in the market and their year on year impact on the market size and share
  • Analyzing the collected data points
  • Bridging the data points to calculate the total global hemophilia treatment market and its various segments
  • Anticipating potential risks
  • Analyzing market forces such as drivers, restraints, and opportunities to assess new growth areas for the global hemophilia treatment market
  • Finalizing the overall size and share of the global hemophilia treatment market

OBJECTIVES:

  • To analyze market trends, opportunities, drivers, and restraints associated with the global hemophilia treatment market
  • To study market response with respect to the mergers and acquisitions in the industry
  • To profile key companies operating in the global hemophilia treatment market and provide their competitive landscape

MARKET SCOPE

The research scope for global hemophilia treatment market is as follows:

By Type

  • Hemophilia A
  • Hemophilia B
  • Others

By Sex

  • Male
  • Female

By Product

  • Recombinant Coagulation Factor Concentrates
  • Plasma Derived Coagulation Factor Concentrates
  • Desmopressin
  • Antifibrinolytic Agents

By Therapy

  • Factor Replacement Therapy
  • Gene Therapy
  • Immune Tolerance Induction therapy

By Distribution Channel

  • Retail Pharmacies
  • Hospitals
  • E-commerce

By Region

  • North America
  • Latin America
  • Europe
  • Asia-Pacific
  • Middle East and Africa

Hemophilia Market: Major players are adopting strategies such as global expansion and product development,  hence promoting growth of the market

Hemophilia is a rare bleeding disorder where one of the blood clotting factors is missing. There are two main types of hemophilia, hemophilia A, and hemophilia B. Hemophilia A is caused by deficient or dysfunctional clotting factor VIII, and hemophilia B due to factor IX deficiency. The deficiency or absence of one of these factors, may disrupt the blood clotting factor. People with bleeding disorders experience extended bleeding after trauma, injury, menstruation, and surgery.

Many major players focus on novel drug development in the treatment of hemophilia. Recently European Commission has approved Roche ‘’Hemlibra’’ for treatment of hemophilia A with factor VIII inhibitors. Japan’s Ministry of Health, Labor, and Welfare (MHLW) has approved CSL Behring’s “AFSTYLA” for the treatment of hemophilia A. Major players are investing in research and development activities for the development of novel drugs that can treat both types of hemophilia.

The treatment of hemophilia depends upon the type of hemophilia and the severity of hemophilia. Gene therapy is a novel approach to the treatment of hemophilia. In this treatment the gene is transferred through IV infusion and provides an individual with hemophilia a function FVIII or FIX gene. Major biotechnology and pharmaceutical companies focus on gene therapy for better treatment and increases the lifespan of patients with hemophilia.

North America held major market share of the global market in 2017. The growth in the region is attributed to growing number of people affected with hemophilia disease.  According to the National Institutes of Health (NIH), approx 200,000 people suffered with hemophilia disease in the United States. Asia-Pacific region is expected to witness the fastest growth during the forecast period owing to growing number of drugs approval, and advancement in diagnostic technology.

TABLE OF CONTENTS

CHAPTER 1. Market Scope and Methodology

1.1. Research methodology

1.2. Research scope & assumptions

1.3. List of data sources

CHAPTER 2. Executive Summary

2.1. Hemophilia Treatment – Market snapshot

CHAPTER 3. Industry Analysis

3.1. Market definition

3.2. Market segmentation

3.3. Key findings of the global hemophilia treatment market

3.4. Value chain analysis

3.5. Market opportunities & trends

3.6. Market dynamics

3.6.1. Market driver analysis

  3.6.1.1. Growing numbers of patients affected with hemophilia

  3.6.1.2. Improvement in diagnosis technology and treatment in developing countries

  3.6.1.3. Growing research and development in gene and replacement therapy

  3.6.1.4. Development of novel drugs for treatment of hhemophilia

3.6.2. Market restraint analysis

           3.6.2.1. High cost of therapy

3.6.3. Industry Analysis-Porters five forces of analysis

CHAPTER 4. Competitive Outlook

4.1. Competitive analysis

4.2. Competitive factors

4.3. Strategies adopted

CHAPTER 5. Global Hemophilia Treatment Market Size and Forecast (2014 – 2024)

5.1. Global Hemophilia Treatment Market, By Type (USD Million)

5.1.1. Hemophilia A

5.1.2. Hemophilia B

5.1.3. Others

5.2. Global Hemophilia Treatment Market, By Sex (USD Million)

5.2.1. Male

5.2.2. Female

5.3. Hemophilia Treatment Market, By Product (USD Million)

5.3.1. Recombinant Coagulation Factor Concentrates

5.3.2. Plasma Derived Coagulation Factor Concentrates

5.3.3. Desmopressin

5.3.4. Antifibrinolytic Agents

5.4. Hemophilia Treatment Market, By Therapy (USD Million)

5.4.1. Factor Replacement Therapy

5.4.2. Gene Therapy

5.4.3. Immune Tolerance Induction (ITI)Therapy

5.5. Hemophilia Treatment Market, By Distribution Channel (USD Million)

        5.5.1. Retail Pharmacies

5.5.2. Hospitals

5.5.3. E-commerce

CHAPTER 6. Global Hemophilia Treatment Market Size and Forecast, By Geography (2014-2024)

6.1. North America Hemophilia Treatment Market

6.1.1. North America Hemophilia Treatment Market, By Type (USD Million)

6.1.2. North America Hemophilia Treatment Market, By Sex (USD Million)

6.1.3. North America Hemophilia Treatment Market, By Product (USD Million)

6.1.4. North America Hemophilia Treatment Market, By Therapy (USD Million)

6.1.5. North America Hemophilia Treatment Market, By Distribution Channel (USD Million)

6.1.6. North America Hemophilia Treatment Market, By Country (USD Million)

  6.1.6.1. U.S.

  6.1.6.2. Canada

6.2. Europe Hemophilia Treatment Market

6.2.1. Europe Hemophilia Treatment Market, By Type (USD Million)

6.2.2. Europe Hemophilia Treatment Market, By Sex (USD Million)

6.2.3. Europe Hemophilia Treatment Market, By Product (USD Million)

6.2.4. Europe Hemophilia Treatment Market, By Therapy (USD Million)

6.2.5. Europe Hemophilia Treatment Market, By Distribution Channel (USD Million)

6.2.6. Europe Hemophilia Treatment Market, By Country (USD Million)

   6.2.6.1. Germany

   6.2.6.2. France

   6.2.6.3. U.K.

   6.2.6.4. Russia

   6.2.6.5. Rest of Europe

6.3. Asia-Pacific Hemophilia Treatment Market

6.3.1. Asia-Pacific Hemophilia Treatment Market, By Type (USD Million)

6.3.2. Asia-Pacific Hemophilia Treatment Market, By Sex (USD Million)

6.3.3. Asia-Pacific Hemophilia Treatment Market, By Product (USD Million)

6.3.4. Asia-Pacific Hemophilia Treatment Market, By Therapy (USD Million)

6.3.5. Asia-Pacific Hemophilia Treatment Market, By Distribution Channel (USD Million)

6.3.6. Asia-Pacific Hemophilia Treatment Market, By Country (USD Million)

   6.3.6.1. China

  6.3.6.2. Australia

  6.3.6.3. Japan

  6.3.6.4. Korea

  6.3.6.5. India

  6.3.6.6. Rest of Asia-Pacific

6.4. Latin America Hemophilia Treatment Market

6.4.1. Latin America Hemophilia Treatment Market, By Type (USD Million)

6.4.2. Latin America Hemophilia Treatment Market, By Sex (USD Million)

6.4.3. Latin America Hemophilia Treatment Market, By Product (USD Million)

6.4.4. Latin America Hemophilia Treatment Market, By Therapy (USD Million)

6.4.5. Latin America Hemophilia Treatment Market, By Distribution Channel (USD Million)

6.4.6. Latin America Hemophilia Treatment Market, By Country (USD Million)

   6.4.6.1. Brazil

   6.4.6.2. Mexico

   6.4.6.3. Rest of Latin America

6.5. Middle East and Africa Hemophilia Treatment Market

6.5.1. Middle East and Africa Hemophilia Treatment Market, By Type (USD Million)

6.5.2. Middle East and Africa Hemophilia Treatment Market, By Sex (USD Million)

6.5.3. Middle East and Africa Hemophilia Treatment Market, By Product (USD Million)

6.5.4. Middle East and Africa Hemophilia Treatment Market, By Therapy (USD Million)

6.5.5. Middle East and Africa Hemophilia Treatment Market, By Distribution Channel (USD Million)

6.5.6. Middle East and Africa Hemophilia Treatment Market, By Country (USD Million)

   6.5.6.1. Saudi Arabia

   6.5.6.2. South Africa

   6.5.6.3. Rest of Middle East and Africa

CHAPTER 7. Key Players and Strategic Developments

7.1. Novo Nordisk A/S

7.1.1. Business Overview

7.1.2. Product and Service Offering

7.1.3. Financial Overview

7.1.4. Strategic Developments

7.2. Sanofi

7.2.1. Business Overview

7.2.2. Product and Service Offering

7.2.3. Financial Overview

7.2.4. Strategic Developments

7.3. Bayer AG

7.3.1. Business Overview

7.3.2. Product and Service Offering

7.3.3. Financial Overview

7.3.4. Strategic Developments

7.4. Pfizer Inc.

7.4.1. Business Overview

7.4.2. Product and Service Offering

7.4.3. Financial Overview

7.4.4. Strategic Developments

7.5. Grifols, S.A.

7.5.1. Business Overview

7.5.2. Product and Service Offering

7.5.3. Financial Overview

7.5.4. Strategic Developments

7.6. Octapharma AG

7.6.1. Business Overview

7.6.2. Product and Service Offering

7.6.3. Financial Overview

7.6.4. Strategic Developments

7.7. Kedrion S.p.A

7.7.1. Business Overview

7.7.2. Product and Service Offering

7.7.3. Financial Overview

7.7.4. Strategic Developments

7.8. Baxter International Inc.

7.8.1. Business Overview

7.8.2. Product and Service Offering

7.8.3. Financial Overview

7.8.4. Strategic Developments

7.9. CSL Behring

7.9.1. Business Overview

7.9.2. Product and Service Offering

7.9.3. Financial Overview

7.9.4. Strategic Developments

7.10. Swedish Orphan Biovitrum AB

7.10.1. Business Overview

7.10.2. Product and Service Offering

7.10.3. Financial Overview

7.10.4. Strategic Developments

7.11. Shire

7.11.1. Business Overview

7.11.2. Product and Service Offering

7.11.3. Financial Overview

7.11.4. Strategic Developments

7.12. F. Hoffmann-La Roche Ltd

7.12.1. Business Overview

7.12.2. Product and Service Offering

7.12.3. Financial Overview

7.12.4. Strategic Developments

Global Hemophilia Treatment Market Outlook, Trend and Opportunity Analysis, Competitive Insights, Actionable Segmentation and Forecast 2024